Intrinsic value of MannKind - MNKD

Previous Close

$1.84

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$1.84

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of MNKD stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  19
  29
  43
  63
  89
  122
  164
  215
  277
  350
  435
  531
  641
  762
  896
  1,042
  1,201
  1,371
  1,553
  1,746
  1,950
  2,164
  2,390
  2,626
  2,872
  3,129
  3,397
  3,676
  3,965
  4,266
Variable operating expenses, $m
  3
  5
  7
  11
  15
  20
  27
  36
  46
  58
  73
  89
  107
  127
  150
  174
  201
  229
  259
  292
  326
  361
  399
  439
  480
  523
  567
  614
  662
  712
Fixed operating expenses, $m
  93
  95
  97
  99
  101
  104
  106
  108
  111
  113
  116
  118
  121
  123
  126
  129
  132
  135
  138
  141
  144
  147
  150
  153
  157
  160
  164
  167
  171
  175
Total operating expenses, $m
  96
  100
  104
  110
  116
  124
  133
  144
  157
  171
  189
  207
  228
  250
  276
  303
  333
  364
  397
  433
  470
  508
  549
  592
  637
  683
  731
  781
  833
  887
Operating income, $m
  -77
  -71
  -61
  -47
  -27
  -2
  31
  71
  120
  178
  246
  325
  413
  511
  620
  739
  868
  1,007
  1,156
  1,313
  1,480
  1,656
  1,841
  2,034
  2,236
  2,447
  2,666
  2,894
  3,132
  3,379
EBITDA, $m
  -72
  -62
  -48
  -28
  -1
  34
  79
  135
  202
  282
  374
  481
  601
  736
  884
  1,046
  1,222
  1,411
  1,613
  1,828
  2,055
  2,294
  2,545
  2,807
  3,082
  3,368
  3,667
  3,977
  4,300
  4,636
Interest expense (income), $m
  9
  14
  -3
  2
  9
  18
  30
  45
  65
  89
  117
  151
  190
  235
  286
  342
  404
  472
  545
  624
  708
  798
  892
  992
  1,096
  1,205
  1,320
  1,439
  1,563
  1,692
  1,826
Earnings before tax, $m
  -91
  -68
  -63
  -56
  -45
  -32
  -15
  6
  32
  61
  96
  134
  178
  226
  278
  335
  397
  462
  532
  605
  683
  764
  849
  938
  1,031
  1,127
  1,227
  1,332
  1,440
  1,553
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  2
  9
  17
  26
  36
  48
  61
  75
  91
  107
  125
  144
  163
  184
  206
  229
  253
  278
  304
  331
  360
  389
  419
Net income, $m
  -91
  -68
  -63
  -56
  -45
  -32
  -15
  5
  23
  45
  70
  98
  130
  165
  203
  245
  290
  337
  388
  442
  498
  558
  620
  685
  752
  823
  896
  972
  1,051
  1,134

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  111
  172
  257
  373
  526
  723
  971
  1,274
  1,640
  2,071
  2,572
  3,145
  3,790
  4,510
  5,302
  6,168
  7,105
  8,112
  9,187
  10,329
  11,536
  12,807
  14,141
  15,538
  16,996
  18,517
  20,101
  21,749
  23,463
  25,244
Adjusted assets (=assets-cash), $m
  111
  172
  257
  373
  526
  723
  971
  1,274
  1,640
  2,071
  2,572
  3,145
  3,790
  4,510
  5,302
  6,168
  7,105
  8,112
  9,187
  10,329
  11,536
  12,807
  14,141
  15,538
  16,996
  18,517
  20,101
  21,749
  23,463
  25,244
Revenue / Adjusted assets
  0.171
  0.169
  0.167
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
  0.169
Average production assets, $m
  44
  68
  101
  147
  207
  284
  382
  501
  645
  815
  1,011
  1,237
  1,491
  1,773
  2,085
  2,426
  2,794
  3,190
  3,613
  4,062
  4,537
  5,037
  5,561
  6,110
  6,684
  7,282
  7,905
  8,553
  9,227
  9,927
Working capital, $m
  -41
  -63
  -94
  -136
  -193
  -265
  -355
  -466
  -600
  -758
  -941
  -1,151
  -1,387
  -1,651
  -1,941
  -2,258
  -2,601
  -2,969
  -3,363
  -3,781
  -4,223
  -4,688
  -5,177
  -5,688
  -6,222
  -6,778
  -7,358
  -7,961
  -8,589
  -9,241
Total debt, $m
  -29
  26
  102
  207
  344
  522
  745
  1,018
  1,347
  1,735
  2,186
  2,701
  3,282
  3,930
  4,643
  5,422
  6,266
  7,172
  8,140
  9,167
  10,254
  11,398
  12,598
  13,855
  15,168
  16,537
  17,962
  19,445
  20,987
  22,590
Total liabilities, $m
  100
  155
  231
  336
  473
  651
  873
  1,147
  1,476
  1,864
  2,315
  2,830
  3,411
  4,059
  4,772
  5,551
  6,395
  7,301
  8,269
  9,296
  10,383
  11,527
  12,727
  13,984
  15,297
  16,666
  18,091
  19,574
  21,116
  22,719
Total equity, $m
  11
  17
  26
  37
  53
  72
  97
  127
  164
  207
  257
  314
  379
  451
  530
  617
  711
  811
  919
  1,033
  1,154
  1,281
  1,414
  1,554
  1,700
  1,852
  2,010
  2,175
  2,346
  2,524
Total liabilities and equity, $m
  111
  172
  257
  373
  526
  723
  970
  1,274
  1,640
  2,071
  2,572
  3,144
  3,790
  4,510
  5,302
  6,168
  7,106
  8,112
  9,188
  10,329
  11,537
  12,808
  14,141
  15,538
  16,997
  18,518
  20,101
  21,749
  23,462
  25,243
Debt-to-equity ratio
  -2.600
  1.490
  3.980
  5.540
  6.550
  7.220
  7.670
  7.990
  8.210
  8.380
  8.500
  8.590
  8.660
  8.710
  8.760
  8.790
  8.820
  8.840
  8.860
  8.880
  8.890
  8.900
  8.910
  8.920
  8.920
  8.930
  8.940
  8.940
  8.950
  8.950
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -91
  -68
  -63
  -56
  -45
  -32
  -15
  5
  23
  45
  70
  98
  130
  165
  203
  245
  290
  337
  388
  442
  498
  558
  620
  685
  752
  823
  896
  972
  1,051
  1,134
Depreciation, amort., depletion, $m
  6
  9
  13
  19
  26
  36
  48
  63
  82
  103
  128
  157
  189
  224
  264
  307
  354
  404
  457
  514
  574
  638
  704
  773
  846
  922
  1,001
  1,083
  1,168
  1,257
Funds from operations, $m
  -85
  -60
  -50
  -37
  -19
  4
  34
  68
  105
  148
  198
  255
  318
  389
  467
  552
  643
  741
  846
  956
  1,073
  1,195
  1,324
  1,458
  1,598
  1,744
  1,897
  2,055
  2,219
  2,390
Change in working capital, $m
  -15
  -22
  -31
  -42
  -56
  -72
  -91
  -111
  -134
  -158
  -183
  -210
  -236
  -263
  -290
  -317
  -343
  -369
  -394
  -418
  -442
  -465
  -488
  -511
  -534
  -557
  -580
  -603
  -627
  -652
Cash from operations, $m
  -70
  -38
  -19
  5
  37
  76
  124
  179
  238
  306
  381
  464
  555
  653
  757
  869
  986
  1,110
  1,239
  1,374
  1,515
  1,661
  1,812
  1,969
  2,132
  2,301
  2,476
  2,658
  2,847
  3,042
Maintenance CAPEX, $m
  -4
  -6
  -9
  -13
  -19
  -26
  -36
  -48
  -63
  -82
  -103
  -128
  -157
  -189
  -224
  -264
  -307
  -354
  -404
  -457
  -514
  -574
  -638
  -704
  -773
  -846
  -922
  -1,001
  -1,083
  -1,168
New CAPEX, $m
  -16
  -24
  -33
  -46
  -60
  -78
  -97
  -119
  -144
  -170
  -197
  -225
  -254
  -283
  -312
  -340
  -368
  -396
  -423
  -449
  -475
  -500
  -525
  -549
  -574
  -598
  -623
  -648
  -674
  -700
Cash from investing activities, $m
  -20
  -30
  -42
  -59
  -79
  -104
  -133
  -167
  -207
  -252
  -300
  -353
  -411
  -472
  -536
  -604
  -675
  -750
  -827
  -906
  -989
  -1,074
  -1,163
  -1,253
  -1,347
  -1,444
  -1,545
  -1,649
  -1,757
  -1,868
Free cash flow, $m
  -90
  -67
  -61
  -53
  -42
  -27
  -9
  11
  31
  54
  81
  111
  144
  181
  221
  264
  311
  360
  412
  468
  526
  586
  650
  716
  785
  857
  932
  1,009
  1,090
  1,174
Issuance/(repayment) of debt, $m
  -186
  55
  77
  104
  138
  177
  223
  273
  329
  388
  451
  515
  581
  647
  714
  779
  843
  906
  968
  1,028
  1,086
  1,144
  1,201
  1,257
  1,313
  1,369
  1,426
  1,483
  1,542
  1,603
Issuance/(repurchase) of shares, $m
  317
  74
  72
  67
  61
  52
  39
  26
  13
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  131
  129
  149
  171
  199
  229
  262
  299
  342
  388
  451
  515
  581
  647
  714
  779
  843
  906
  968
  1,028
  1,086
  1,144
  1,201
  1,257
  1,313
  1,369
  1,426
  1,483
  1,542
  1,603
Total cash flow (excl. dividends), $m
  42
  62
  87
  118
  157
  202
  253
  311
  374
  443
  532
  626
  725
  829
  935
  1,043
  1,154
  1,266
  1,380
  1,495
  1,612
  1,730
  1,851
  1,973
  2,098
  2,226
  2,357
  2,493
  2,632
  2,777
Retained Cash Flow (-), $m
  -317
  -74
  -72
  -67
  -61
  -52
  -39
  -30
  -37
  -43
  -50
  -57
  -65
  -72
  -79
  -87
  -94
  -101
  -108
  -114
  -121
  -127
  -133
  -140
  -146
  -152
  -158
  -165
  -171
  -178
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -275
  -12
  15
  51
  96
  150
  214
  280
  337
  400
  482
  569
  661
  757
  855
  957
  1,060
  1,166
  1,273
  1,381
  1,491
  1,603
  1,717
  1,833
  1,952
  2,074
  2,199
  2,328
  2,461
  2,599
Discount rate, %
  5.60
  5.88
  6.17
  6.48
  6.81
  7.15
  7.50
  7.88
  8.27
  8.69
  9.12
  9.58
  10.06
  10.56
  11.09
  11.64
  12.22
  12.84
  13.48
  14.15
  14.86
  15.60
  16.38
  17.20
  18.06
  18.96
  19.91
  20.91
  21.95
  23.05
PV of cash for distribution, $m
  -261
  -11
  13
  40
  69
  99
  129
  153
  165
  174
  184
  190
  190
  186
  177
  164
  149
  133
  115
  98
  81
  66
  52
  41
  31
  23
  16
  11
  8
  5
Current shareholders' claim on cash, %
  50.0
  6.5
  1.3
  0.3
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

FINANCIAL RATIOS  of  MannKind (MNKD)

Valuation Ratios
P/E Ratio 1.4
Price to Sales 1
Price to Book -1
Price to Tangible Book
Price to Cash Flow -2.3
Price to Free Cash Flow -2.2
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -90%
Cap. Spend. - 3 Yr. Gr. Rate -34%
Financial Strength
Quick Ratio 0
Current Ratio 0.2
LT Debt to Equity -42.4%
Total Debt to Equity -81%
Interest Coverage 15
Management Effectiveness
Return On Assets 115.9%
Ret/ On Assets - 3 Yr. Avg. -26%
Return On Total Capital -147.4%
Ret/ On T. Cap. - 3 Yr. Avg. -1720.4%
Return On Equity -47.2%
Return On Equity - 3 Yr. Avg. 167.8%
Asset Turnover 1.5
Profitability Ratios
Gross Margin 71.4%
Gross Margin - 3 Yr. Avg. 23.8%
EBITDA Margin 79.4%
EBITDA Margin - 3 Yr. Avg. 26.5%
Operating Margin 80%
Oper. Margin - 3 Yr. Avg. 26.7%
Pre-Tax Margin 72%
Pre-Tax Margin - 3 Yr. Avg. 24%
Net Profit Margin 72%
Net Profit Margin - 3 Yr. Avg. 24%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

MNKD stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MNKD stock intrinsic value calculation we used $11.745 million for the last fiscal year's total revenue generated by MannKind. The default revenue input number comes from 0001 income statement of MannKind. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MNKD stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.6%, whose default value for MNKD is calculated based on our internal credit rating of MannKind, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of MannKind.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MNKD stock the variable cost ratio is equal to 16.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $91 million in the base year in the intrinsic value calculation for MNKD stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 8.7% for MannKind.

Corporate tax rate of 27% is the nominal tax rate for MannKind. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MNKD stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MNKD are equal to 232.7%.

Life of production assets of 7.9 years is the average useful life of capital assets used in MannKind operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MNKD is equal to -216.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-214.732 million for MannKind - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 140.025 million for MannKind is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of MannKind at the current share price and the inputted number of shares is $0.3 billion.

RELATED COMPANIES Price Int.Val. Rating
NVO Novo Nordisk A 44.54 128.58  str.buy
LLY Eli Lilly 113.20 67.15  sell
ACOR Acorda Therape 18.40 16.91  sell
CTLT Catalent 37.94 30.16  sell
AMPH Amphastar Phar 21.00 1.57  str.sell

COMPANY NEWS

▶ MannKind: 3Q Earnings Snapshot   [Nov-01-18 09:33AM  Associated Press]
▶ Why MannKind Corp. Soared 16.4% Tuesday   [Oct-16-18 05:22PM  Motley Fool]
▶ MannKind Stock History   [Sep-27-18 02:25PM  Motley Fool]
▶ Is MannKind Corporation Stock a Buy?   [Sep-08-18 07:50PM  Motley Fool]
▶ A New Deal Moves MannKind Back From the Brink   [Sep-06-18 03:02PM  Motley Fool]
▶ Why MannKind Stock Is Skyrocketing Today   [Sep-04-18 11:27AM  InvestorPlace]
▶ MannKind Corporation to Present at Upcoming Conferences   [Aug-29-18 09:00AM  GlobeNewswire]
▶ Los Angeles stocks that are driving Wall Street's latest bull run   [Aug-23-18 02:31PM  American City Business Journals]
▶ Why MannKind Corporation Stock Is Tanking Again Today   [Aug-06-18 04:30PM  Motley Fool]
▶ Can MannKind Corporation Avert Bankruptcy?   [Aug-03-18 01:34PM  Motley Fool]
▶ MannKind: 2Q Earnings Snapshot   [05:20PM  Associated Press]
▶ Should Biotech Investors Fear Dilution?   [Jul-21-18 08:25AM  Motley Fool]
▶ MannKind Set to Join Russell 3000® Index   [Jun-25-18 09:00AM  GlobeNewswire]
▶ MannKind to Host Institutional Investor and Analyst Meeting   [Jun-20-18 04:01PM  GlobeNewswire]
▶ MannKind Establishes Market Price Stock Purchase Plan   [Jun-05-18 04:30PM  GlobeNewswire]
▶ MannKind: 1Q Earnings Snapshot   [May-09-18 04:54PM  Associated Press]
▶ Why MannKind Corporation Stock Broke Down in April   [May-08-18 07:28AM  Motley Fool]
▶ MannKind (MNKD) Enters Oversold Territory   [Apr-13-18 08:19AM  Zacks]
▶ Here's Why MannKind Corporation Stock Is Tanking Today   [Apr-06-18 08:27AM  Motley Fool]
▶ Could MannKind Corporation Be a Millionaire-Maker Stock?   [Mar-08-18 01:00PM  Motley Fool]
▶ 3 Bright Spots in MannKind Corporation's Q4 Update   [Feb-28-18 09:18AM  Motley Fool]
▶ MannKind reports 4Q loss   [Feb-27-18 05:37PM  Associated Press]
▶ Here's Why MannKind Briefly Spiked Today   [Jan-29-18 04:52PM  Motley Fool]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.